West Pharmaceutical Services (West Pharmaceutical Services) Debt-to-Equity : 0.11 (As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

What is West Pharmaceutical Services Debt-to-Equity?

West Pharmaceutical Services's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $152 Mil. West Pharmaceutical Services's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $157 Mil. West Pharmaceutical Services's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,881 Mil. West Pharmaceutical Services's debt to equity for the quarter that ended in Dec. 2023 was 0.11.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for West Pharmaceutical Services's Debt-to-Equity or its related term are showing as below:

WST' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.11 Med: 0.17 Max: 0.35
Current: 0.11

During the past 13 years, the highest Debt-to-Equity Ratio of West Pharmaceutical Services was 0.35. The lowest was 0.11. And the median was 0.17.

WST's Debt-to-Equity is ranked better than
65.73% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs WST: 0.11

West Pharmaceutical Services Debt-to-Equity Historical Data

The historical data trend for West Pharmaceutical Services's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Debt-to-Equity Chart

West Pharmaceutical Services Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.21

0.18

0.14

0.12

0.11

West Pharmaceutical Services Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.12	0.11	0.11	0.11	0.11

Competitive Comparison of West Pharmaceutical Services's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Debt-to-Equity falls into.

West Pharmaceutical Services Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

West Pharmaceutical Services's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(151.7	+	157.3)	/	2881
	=	0.11

West Pharmaceutical Services's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(151.7	+	157.3)	/	2881
	=	0.11

West Pharmaceutical Services (NYSE:WST) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

West Pharmaceutical Services Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services (West Pharmaceutical Services) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

WPS:Germany

Address

530 Herman O. West Drive, Exton, PA, USA, 19341-0645

Website

https://www.westpharma.com

West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.

Executives

Chad Winters	officer: VP, CAO & Controller	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Charles Witherspoon	officer: VP & Treasurer	530 HERMAN O WEST DRIVE, EXTON PA 19341
Annette F Favorite	officer: Sr. VP Human Resources Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark	officer: Senior Vice President	530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai	officer: VP Corp Development & Strategy	530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Silji Abraham	officer: Chief Digital & Trans Officer	5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Eric Mark Green	officer: Chief Executive Officer	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Bernard Birkett	officer: Sr VP, CFO & Treasurer	1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Thomas W Hofmann	director	FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Stephen H Lockhart	director	C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph	director	9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay	officer: SVP, GC & Corporate Secretary	530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller	officer: Sr. VP, GC & Corp. Sec.	530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo	officer: SVP, Glob Ops and Supply Chain	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel	director	940 WINTER STREET, WALTHAM MA 02451